Emergent BioSolutions Inc.

Signal Note: Deerfield Exit from EBS

Deerfield Management's full exit from Emergent BioSolutions suggests deteriorating conviction in the CDMO/vaccines platform, likely reflecting execution risk or margin pressure in contract manufacturing amid oversupply in the sector. This carries marginal signaling weight given the small position size ($17K), though it warrants monitoring if other specialist healthcare investors follow suit. No near-term catalyst or liquidity concerns are evident.